Se connecter Inscription gratuite

Abeona Therapeutics Inc Marge bénéficiaire

Quel est le Marge bénéficiaire de Abeona Therapeutics Inc?

Le Marge bénéficiaire de Abeona Therapeutics Inc est -1,548.23%

Quelle est la définition de Marge bénéficiaire?



La marge bénéficiaire est une mesure de la rentabilité et est calculée en calculant le bénéfice net en tant que pourcentage du chiffre d'affaires.

Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.

Marge bénéficiaire des entreprises dans Health Care secteur sur NASDAQ par rapport à Abeona Therapeutics Inc

Que fait Abeona Therapeutics Inc?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

Entreprises avec marge bénéficiaire similaire à Abeona Therapeutics Inc